|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5128257A
(en)
|
1987-08-31 |
1992-07-07 |
Baer Bradford W |
Electroporation apparatus and process
|
|
DE68925030T2
(de)
|
1988-01-21 |
1996-07-25 |
Massachusetts Inst Technology |
Molekültransport durch gewebe mit der verwendung von elektroporation.
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
EP0401384B1
(en)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
CA2019758C
(en)
|
1990-06-25 |
2001-09-04 |
Kevin L. Firth |
Improved electroporation device and method
|
|
US5137817A
(en)
|
1990-10-05 |
1992-08-11 |
Amoco Corporation |
Apparatus and method for electroporation
|
|
US5173158A
(en)
|
1991-07-22 |
1992-12-22 |
Schmukler Robert E |
Apparatus and methods for electroporation and electrofusion
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5304120A
(en)
|
1992-07-01 |
1994-04-19 |
Btx Inc. |
Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
|
|
US5273525A
(en)
|
1992-08-13 |
1993-12-28 |
Btx Inc. |
Injection and electroporation apparatus for drug and gene delivery
|
|
US5318514A
(en)
|
1992-08-17 |
1994-06-07 |
Btx, Inc. |
Applicator for the electroporation of drugs and genes into surface cells
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
WO1996000295A1
(en)
|
1994-06-27 |
1996-01-04 |
The Johns Hopkins University |
Targeted gene delivery system
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US6010613A
(en)
|
1995-12-08 |
2000-01-04 |
Cyto Pulse Sciences, Inc. |
Method of treating materials with pulsed electrical fields
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
JP2001508302A
(ja)
|
1997-01-10 |
2001-06-26 |
ライフ テクノロジーズ，インコーポレイテッド |
胚性幹細胞血清置換
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
DK0973928T3
(da)
|
1997-03-11 |
2010-08-09 |
Univ Minnesota |
DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
|
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
AU2001265756A1
(en)
|
2000-04-27 |
2001-11-07 |
Max-Delbruck-Centrum Fur Molekulare Medizin |
Sleeping beauty, a transposon vector with a broad host range for the genetic transfprmation in vertebrates
|
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
|
EP2316490A3
(en)
|
2000-10-31 |
2012-02-01 |
PR Pharmaceuticals, Inc. |
Methods and compositions for enhanced delivery of bioactive molecules
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
KR20050000380A
(ko)
|
2002-04-09 |
2005-01-03 |
교와 핫꼬 고교 가부시끼가이샤 |
게놈이 개변된 세포
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
ATE480562T1
(de)
|
2002-10-15 |
2010-09-15 |
Facet Biotech Corp |
Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
JP4762156B2
(ja)
|
2004-01-12 |
2011-08-31 |
アプライド モレキュラー エボリューション，インコーポレイテッド |
Ｆｃ領域変異体
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
MX2007014139A
(es)
|
2005-05-14 |
2008-10-09 |
Univ Fudan |
Piggybac como una herramienta para manipulacion genetica y analisis en vertebrados.
|
|
US9228180B2
(en)
|
2007-07-04 |
2016-01-05 |
Max-Delbruck-Centrum Fur Molekulare Medizin |
Polypeptide variants of sleeping beauty transposase
|
|
WO2010085699A2
(en)
|
2009-01-23 |
2010-07-29 |
The Johns Hopkins University |
Mammalian piggybac transposon and methods of use
|
|
US20110311506A1
(en)
|
2009-02-25 |
2011-12-22 |
The Johns Hopkins University |
Piggybac transposon variants and methods of use
|
|
EP4733396A2
(en)
|
2009-02-26 |
2026-04-29 |
Poseida Therapeutics, Inc. |
Hyperactive piggybac transposases
|
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
|
WO2011159369A1
(en)
|
2010-06-14 |
2011-12-22 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of tal effector and foki fusion protein
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
US20140115726A1
(en)
|
2011-04-05 |
2014-04-24 |
Cellectis |
New tale-protein scaffolds and uses thereof
|
|
WO2013016600A2
(en)
|
2011-07-28 |
2013-01-31 |
The Trustees Of The University Of Pennsylvania |
Methods and reagents for diagnosing conditions and characterization of tumor cells associated with serous fluids
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
SG10201806573TA
(en)
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
US10815500B2
(en)
|
2012-06-05 |
2020-10-27 |
Cellectis |
Transcription activator-like effector (TALE) fusion protein
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
ES2778033T3
(es)
|
2012-11-16 |
2020-08-07 |
Poseida Therapeutics Inc |
Enzimas específicas de sitio y métodos de uso
|
|
WO2014133567A1
(en)
|
2013-03-01 |
2014-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
|
EP3019618B1
(en)
|
2013-07-12 |
2018-10-31 |
University of South Alabama |
Minimal piggybac vectors for genome integration
|
|
US10927384B2
(en)
|
2014-04-09 |
2021-02-23 |
Dna Twopointo Inc. |
DNA vectors, transposons and transposases for eukaryotic genome modification
|
|
UA123821C2
(uk)
|
2014-06-11 |
2021-06-09 |
Полібіосепт Гмбх |
Композиція для експансії лімфоцитів in vitro
|
|
WO2015195798A1
(en)
|
2014-06-17 |
2015-12-23 |
Poseida Therapeutics, Inc. |
A method for directing proteins to specific loci in the genome and uses thereof
|
|
CA2952618A1
(en)
|
2014-06-17 |
2015-12-23 |
Poseida Therapeutics, Inc. |
Methods and compositions for in vivo non-covalent linking
|
|
JP2018521689A
(ja)
|
2015-06-17 |
2018-08-09 |
ポセイダ セラピューティクス， インコーポレイテッド |
タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
|
|
US12048717B2
(en)
|
2016-06-03 |
2024-07-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (TILS)
|
|
CN110099998A
(zh)
|
2016-10-26 |
2019-08-06 |
艾欧凡斯生物治疗公司 |
冷冻保存的肿瘤浸润淋巴细胞的再刺激
|
|
CA3043597A1
(en)
|
2016-11-10 |
2018-05-17 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
AU2018207283C1
(en)
|
2017-01-10 |
2024-05-02 |
Nektar Therapeutics |
Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
IL321812A
(en)
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
US20210115453A1
(en)
|
2017-08-31 |
2021-04-22 |
Poseida Therapeutics, Inc. |
Transposon system and methods of use
|
|
WO2019126578A1
(en)
|
2017-12-20 |
2019-06-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
|
US12453697B2
(en)
|
2018-11-05 |
2025-10-28 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
MA54952A
(fr)
|
2019-02-06 |
2022-05-11 |
Synthorx Inc |
Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
|
|
WO2020232029A1
(en)
*
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
EP4048295A1
(en)
*
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
JP2023503652A
(ja)
*
|
2019-11-27 |
2023-01-31 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
腫瘍微小環境における免疫抑制に打ち勝つための操作されたｔ細胞及び腫瘍浸潤リンパ球
|
|
WO2021226061A1
(en)
*
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CA3206549A1
(en)
*
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
CN118019546A
(zh)
*
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
US20240269180A1
(en)
*
|
2021-05-17 |
2024-08-15 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|